| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | shikonin | GDSC1000 | pan-cancer | AAC | -0.048 | 0.1 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.063 | 0.2 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.2 |